Concepts (170)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 59 | 2023 | 3011 | 5.550 |
Why?
|
| Magnetic Resonance Imaging | 44 | 2023 | 3448 | 4.310 |
Why?
|
| Lymph Nodes | 8 | 2021 | 548 | 2.270 |
Why?
|
| Contrast Media | 35 | 2023 | 1091 | 2.260 |
Why?
|
| Axilla | 11 | 2021 | 104 | 2.120 |
Why?
|
| Lymphatic Metastasis | 11 | 2017 | 502 | 2.040 |
Why?
|
| Ultrasonography, Mammary | 7 | 2013 | 83 | 1.770 |
Why?
|
| Carcinoma, Ductal, Breast | 6 | 2021 | 159 | 1.570 |
Why?
|
| Image Interpretation, Computer-Assisted | 14 | 2018 | 688 | 1.460 |
Why?
|
| Breast | 13 | 2022 | 292 | 1.370 |
Why?
|
| Image Enhancement | 13 | 2021 | 567 | 1.350 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 13 | 2020 | 469 | 1.260 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 5 | 2021 | 116 | 1.250 |
Why?
|
| Gadolinium DTPA | 13 | 2015 | 264 | 1.200 |
Why?
|
| Sensitivity and Specificity | 26 | 2023 | 2015 | 1.010 |
Why?
|
| ROC Curve | 19 | 2015 | 781 | 0.920 |
Why?
|
| Mammography | 9 | 2021 | 472 | 0.880 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 5 | 2022 | 302 | 0.860 |
Why?
|
| Receptor, ErbB-2 | 5 | 2023 | 246 | 0.810 |
Why?
|
| Radiologists | 1 | 2021 | 46 | 0.740 |
Why?
|
| Biopsy | 13 | 2022 | 1184 | 0.730 |
Why?
|
| Middle Aged | 49 | 2023 | 25974 | 0.720 |
Why?
|
| Radiography, Thoracic | 9 | 2006 | 322 | 0.710 |
Why?
|
| Female | 65 | 2023 | 46200 | 0.710 |
Why?
|
| Diagnosis, Differential | 20 | 2022 | 1597 | 0.700 |
Why?
|
| Aged | 38 | 2023 | 19165 | 0.680 |
Why?
|
| Diagnosis, Computer-Assisted | 7 | 2011 | 333 | 0.670 |
Why?
|
| Adult | 41 | 2023 | 26607 | 0.650 |
Why?
|
| Biopsy, Needle | 3 | 2010 | 233 | 0.610 |
Why?
|
| Mass Screening | 6 | 2018 | 636 | 0.610 |
Why?
|
| Neoadjuvant Therapy | 7 | 2023 | 377 | 0.600 |
Why?
|
| Humans | 81 | 2023 | 89349 | 0.590 |
Why?
|
| Kinetics | 9 | 2023 | 1528 | 0.580 |
Why?
|
| Retrospective Studies | 25 | 2023 | 9057 | 0.560 |
Why?
|
| Aged, 80 and over | 18 | 2020 | 6811 | 0.460 |
Why?
|
| Observer Variation | 14 | 2020 | 610 | 0.460 |
Why?
|
| User-Computer Interface | 3 | 2012 | 187 | 0.450 |
Why?
|
| Ultrasonography, Interventional | 2 | 2013 | 123 | 0.410 |
Why?
|
| Diagnostic Imaging | 2 | 2013 | 479 | 0.390 |
Why?
|
| Lung Diseases, Interstitial | 4 | 2005 | 260 | 0.380 |
Why?
|
| Organometallic Compounds | 3 | 2016 | 134 | 0.360 |
Why?
|
| Lung Neoplasms | 11 | 2008 | 2362 | 0.350 |
Why?
|
| Tomography, Spiral Computed | 3 | 2004 | 77 | 0.350 |
Why?
|
| Neoplasm Staging | 8 | 2018 | 2018 | 0.340 |
Why?
|
| Carcinoma | 1 | 2013 | 443 | 0.340 |
Why?
|
| Lung Diseases | 4 | 2004 | 269 | 0.310 |
Why?
|
| Solitary Pulmonary Nodule | 7 | 2006 | 139 | 0.300 |
Why?
|
| Decision Making | 1 | 2013 | 667 | 0.300 |
Why?
|
| Reproducibility of Results | 13 | 2018 | 2758 | 0.280 |
Why?
|
| Mastectomy, Segmental | 2 | 2021 | 101 | 0.280 |
Why?
|
| Ultrasonography | 3 | 2017 | 712 | 0.270 |
Why?
|
| Prospective Studies | 10 | 2022 | 4289 | 0.260 |
Why?
|
| Young Adult | 8 | 2021 | 6312 | 0.260 |
Why?
|
| Meglumine | 2 | 2016 | 38 | 0.250 |
Why?
|
| Pattern Recognition, Automated | 4 | 2011 | 217 | 0.250 |
Why?
|
| Calcinosis | 4 | 2011 | 230 | 0.250 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2021 | 487 | 0.240 |
Why?
|
| Image Processing, Computer-Assisted | 5 | 2017 | 1242 | 0.230 |
Why?
|
| Artificial Intelligence | 2 | 2023 | 322 | 0.230 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2017 | 72 | 0.220 |
Why?
|
| Imaging, Three-Dimensional | 4 | 2016 | 598 | 0.220 |
Why?
|
| Breast Density | 2 | 2020 | 36 | 0.210 |
Why?
|
| Preoperative Care | 2 | 2016 | 396 | 0.210 |
Why?
|
| Incidental Findings | 2 | 2013 | 98 | 0.190 |
Why?
|
| Algorithms | 8 | 2017 | 1877 | 0.190 |
Why?
|
| Reference Standards | 1 | 2021 | 144 | 0.180 |
Why?
|
| Radiographic Image Enhancement | 4 | 2009 | 463 | 0.170 |
Why?
|
| Fibroadenoma | 1 | 2019 | 9 | 0.170 |
Why?
|
| Prognosis | 3 | 2013 | 3783 | 0.170 |
Why?
|
| Microvessels | 1 | 2018 | 69 | 0.160 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 1072 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2005 | 2661 | 0.150 |
Why?
|
| Computer Simulation | 3 | 2015 | 1097 | 0.150 |
Why?
|
| BRCA1 Protein | 1 | 2018 | 204 | 0.140 |
Why?
|
| Subtraction Technique | 3 | 2006 | 132 | 0.140 |
Why?
|
| Information Storage and Retrieval | 3 | 2013 | 121 | 0.140 |
Why?
|
| Clinical Competence | 3 | 2009 | 784 | 0.140 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2018 | 105 | 0.140 |
Why?
|
| False Negative Reactions | 2 | 2013 | 63 | 0.140 |
Why?
|
| Early Detection of Cancer | 2 | 2018 | 416 | 0.130 |
Why?
|
| Fourier Analysis | 1 | 2016 | 126 | 0.130 |
Why?
|
| Adipose Tissue | 2 | 2008 | 259 | 0.120 |
Why?
|
| Metabolic Clearance Rate | 1 | 2015 | 120 | 0.120 |
Why?
|
| Area Under Curve | 5 | 2018 | 337 | 0.120 |
Why?
|
| Radiography | 3 | 2012 | 809 | 0.120 |
Why?
|
| Support Vector Machine | 1 | 2013 | 25 | 0.110 |
Why?
|
| Signal-To-Noise Ratio | 3 | 2019 | 103 | 0.110 |
Why?
|
| Genomics | 1 | 2019 | 762 | 0.110 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2013 | 36 | 0.110 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 1431 | 0.110 |
Why?
|
| Medical Records | 1 | 2013 | 120 | 0.110 |
Why?
|
| Radiology Information Systems | 1 | 2013 | 79 | 0.110 |
Why?
|
| Models, Theoretical | 3 | 2018 | 491 | 0.110 |
Why?
|
| Phenotype | 2 | 2019 | 2440 | 0.100 |
Why?
|
| Breast Diseases | 2 | 2011 | 100 | 0.100 |
Why?
|
| Echo-Planar Imaging | 2 | 2017 | 52 | 0.100 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2012 | 103 | 0.100 |
Why?
|
| Predictive Value of Tests | 2 | 2013 | 1723 | 0.100 |
Why?
|
| Postoperative Period | 1 | 2012 | 302 | 0.100 |
Why?
|
| Illinois | 1 | 2013 | 480 | 0.100 |
Why?
|
| Lymph Node Excision | 2 | 2013 | 220 | 0.100 |
Why?
|
| Prevalence | 2 | 2013 | 1243 | 0.090 |
Why?
|
| Precision Medicine | 1 | 2015 | 410 | 0.090 |
Why?
|
| Models, Biological | 2 | 2015 | 1765 | 0.090 |
Why?
|
| False Positive Reactions | 3 | 2005 | 223 | 0.090 |
Why?
|
| Risk Assessment | 2 | 2018 | 2303 | 0.090 |
Why?
|
| Computer Terminals | 1 | 2009 | 7 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2022 | 1365 | 0.080 |
Why?
|
| Adolescent | 2 | 2019 | 9263 | 0.080 |
Why?
|
| Carcinoma, Ductal | 1 | 2008 | 18 | 0.080 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2008 | 38 | 0.080 |
Why?
|
| Carcinoma, Lobular | 1 | 2008 | 81 | 0.080 |
Why?
|
| Feasibility Studies | 3 | 2017 | 780 | 0.070 |
Why?
|
| Artifacts | 2 | 2018 | 247 | 0.070 |
Why?
|
| Ribs | 1 | 2006 | 46 | 0.070 |
Why?
|
| Radiology | 2 | 2008 | 201 | 0.060 |
Why?
|
| Lung | 4 | 2005 | 1263 | 0.060 |
Why?
|
| Risk Factors | 2 | 2014 | 5498 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2023 | 8241 | 0.060 |
Why?
|
| Radiology, Interventional | 1 | 2004 | 69 | 0.060 |
Why?
|
| Neoplasms | 1 | 2018 | 3041 | 0.050 |
Why?
|
| Intracranial Aneurysm | 1 | 2004 | 175 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2004 | 1862 | 0.050 |
Why?
|
| Quality Control | 2 | 2018 | 117 | 0.050 |
Why?
|
| Anthracyclines | 1 | 2022 | 38 | 0.050 |
Why?
|
| Hormones | 1 | 2022 | 139 | 0.050 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2004 | 274 | 0.050 |
Why?
|
| Machine Learning | 1 | 2023 | 258 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2015 | 871 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2022 | 1214 | 0.040 |
Why?
|
| Smoking | 1 | 2003 | 621 | 0.040 |
Why?
|
| Gadolinium | 1 | 2019 | 103 | 0.040 |
Why?
|
| Radiation Dosage | 3 | 2004 | 226 | 0.040 |
Why?
|
| Electric Conductivity | 1 | 2018 | 144 | 0.040 |
Why?
|
| Male | 7 | 2005 | 42410 | 0.040 |
Why?
|
| Quality Assurance, Health Care | 1 | 2018 | 225 | 0.040 |
Why?
|
| Time | 1 | 2016 | 76 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 1714 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1941 | 0.030 |
Why?
|
| Entropy | 1 | 2015 | 39 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 2869 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2015 | 306 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 1150 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2013 | 106 | 0.030 |
Why?
|
| Diagnostic Errors | 2 | 2005 | 160 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2014 | 174 | 0.030 |
Why?
|
| Software | 1 | 2017 | 665 | 0.030 |
Why?
|
| Apoptosis | 1 | 2019 | 1717 | 0.030 |
Why?
|
| Adenocarcinoma | 3 | 2004 | 1194 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 2566 | 0.020 |
Why?
|
| Fats | 1 | 2011 | 12 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2014 | 393 | 0.020 |
Why?
|
| Biomarkers | 1 | 2018 | 1767 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2013 | 576 | 0.020 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2014 | 152 | 0.020 |
Why?
|
| Injections | 1 | 2010 | 116 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 899 | 0.020 |
Why?
|
| Biological Transport | 1 | 2010 | 401 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2018 | 2340 | 0.020 |
Why?
|
| Liquid Crystals | 1 | 2009 | 12 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 225 | 0.020 |
Why?
|
| Mutation | 1 | 2018 | 4143 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2006 | 371 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2004 | 152 | 0.010 |
Why?
|
| Carcinoma, Small Cell | 1 | 2004 | 133 | 0.010 |
Why?
|
| Japan | 1 | 2003 | 304 | 0.010 |
Why?
|
| Time Factors | 1 | 2008 | 5337 | 0.010 |
Why?
|
| Incidence | 1 | 2003 | 1595 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2004 | 3666 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2004 | 1096 | 0.010 |
Why?
|